

assay as follows: Reconstitute as directed in the labeling. Dilute an aliquot with 0.1M potassium phosphate buffer, pH 4.5 (solution 4), to the reference concentration of 0.100 microgram of minocycline per milliliter (estimated).

(2) *Sterility*. Proceed as directed in § 436.20 of this chapter, using the method described in paragraph (e)(1) of that section.

(3) *Moisture*. Proceed as directed in § 436.201 of this chapter.

(4) *pH*. Proceed as directed in § 436.202 of this chapter, using the drug reconstituted as directed in the labeling.

§ 460.66 Oleandomycin phosphate diagnostic sensitivity powder.

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity*. Oleandomycin phosphate diagnostic sensitivity powder is oleandomycin phosphate, with or without one or more suitable buffers and diluents, packaged in vials and intended for use in clinical laboratories, for determining in vitro the sensitivity of microorganisms to oleandomycin. Each vial contains oleandomycin phosphate equivalent to 20 milligrams of oleandomycin. The potency of each immediate container is satisfactory if it contains not less than 90 percent and not more than 115 percent of its labeled content. It is sterile. Its moisture content is not more than 5.0 percent. When reconstituted as directed in the labeling, its pH is not less than 4.0 and not more than 7.0. Each other substance used, if its name is recognized in the U.S.P. or N.F., conforms to the standards prescribed therefor by such official compendium.

(2) *Packaging*. The immediate container shall be of colorless, transparent glass and it shall be a tight container as defined by the U.S.P. It shall be so sealed that the contents cannot be used without destroying such seal. It shall be of appropriate size to permit the addition of 20 milliliters of sterile diluent when preparing a stock solution for use in making further dilutions for microbial susceptibility testing.

(3) *Labeling*. In addition to the requirements of § 432.5(a)(3) of this chapter, each package shall bear on its

label or labeling, as hereinafter indicated, the following:

(i) On its outside wrapper or container and on the immediate container:

(a) The statement “For laboratory diagnostic use only.”

(b) The statement “Sterile.”

(c) The batch mark.

(d) The number of milligrams of oleandomycin in each immediate container.

(ii) On the circular or other labeling within or attached to the package, adequate information for use of the drug in the clinical laboratory.

(4) *Requests for certification; samples*. In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The oleandomycin phosphate used in making the batch for potency, moisture, pH, and identity.

(b) The batch for potency, sterility, moisture, and pH.

(ii) Samples required:

(a) The oleandomycin phosphate used in making the batch: 10 packages, each containing approximately 500 milligrams.

(b) The batch:

(1) For all tests except sterility: A minimum of 20 immediate containers.

(2) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation.

(b) *Tests and methods of assay—(1) Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Reconstitute as directed in the labeling. Dilute an aliquot with 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to the prescribed reference concentration.

(2) *Sterility*. Proceed as directed in § 436.20 of this chapter, using the method described in paragraph (e)(1) of that section.

(3) *Moisture*. Proceed as directed in § 436.201 of this chapter.

(4) *pH*. Proceed as directed in § 436.202 of this chapter, using the drug reconstituted as directed in the labeling.

§ 460.70 Oxytetracycline hydrochloride diagnostic sensitivity powder.

(a) *Requirements for certification—(1) Standards of identity, strength, quality,*

and purity. Oxytetracycline hydrochloride diagnostic sensitivity powder is crystalline oxytetracycline hydrochloride, with or without one or more suitable buffers and diluents, packaged in vials and intended for use in clinical laboratories for determining in vitro the sensitivity of microorganisms to oxytetracycline. Each vial contains oxytetracycline hydrochloride equivalent to 20 milligrams of oxytetracycline. The potency of each immediate container is satisfactory if it contains not less than 90 percent and not more than 115 percent of its labeled content. It is sterile. Its loss on drying is not more than 2.0 percent. When reconstituted as directed in the labeling, its pH is not less than 2.0 and not more than 3.5. The oxytetracycline hydrochloride used conforms to the standards prescribed by § 446.67a(a)(1) (i), (vi), (vii), (viii), and (ix) of this chapter.

(2) *Packaging.* The immediate container shall be of colorless, transparent glass and it shall be a tight container as defined by the U.S.P. It shall be so sealed that the contents cannot be used without destroying such seal. It shall be of appropriate size to permit the addition of 20 milliliters of sterile diluent when preparing a stock solution for use in making further dilutions for microbial susceptibility testing.

(3) *Labeling.* In addition to the requirements of § 432.5(a)(3) of this chapter, each package shall bear on its label or labeling, as hereinafter indicated, the following:

(i) On its outside wrapper or container and on the immediate container:

(a) The statement "For laboratory diagnostic use only".

(b) The statement "Sterile".

(c) The batch mark.

(d) The number of milligrams of oxytetracycline in each immediate container.

(ii) On the circular or other labeling within or attached to the package, adequate information for use of the drug in the clinical laboratory.

(4) *Requests for certification; samples.* In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The oxytetracycline hydrochloride used in making the batch for

potency, moisture, pH, crystallinity, absorptivity, and identity.

(b) The batch for potency, sterility, loss on drying, and pH.

(ii) Samples required:

(a) The oxytetracycline hydrochloride used in making the batch: 10 packages, each containing approximately 300 milligrams.

(b) The batch:

(1) For all tests except sterility: A minimum of 30 immediate containers.

(2) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation.

(b) *Tests and methods of assay—(1) Potency.* Proceed as directed in § 436.106 of this chapter, preparing the sample for assay as follows: Reconstitute as directed in the labeling. Dilute an aliquot with 0.1M potassium phosphate buffer, pH 4.5 (solution 4), to the prescribed reference concentration.

(2) *Sterility.* Proceed as directed in § 436.20 of this chapter, using the method described in paragraph (e) (1) of that section.

(3) *Loss on drying.* Proceed as directed in § 436.200(b) of this chapter.

(4) *pH.* Proceed as directed in § 436.202 of this chapter, using the drug reconstituted as directed in the labeling.

§ 460.75 Potassium penicillin G diagnostic sensitivity powder.

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Potassium penicillin G diagnostic sensitivity powder is crystalline potassium penicillin G, with or without one or more suitable buffers and diluents, packaged in vials and intended for use in clinical laboratories for determining in vitro the sensitivity of microorganisms to penicillin G. Each vial contains 20,000 units of penicillin G. The potency of each immediate container is satisfactory if it contains not less than 90 percent and not more than 115 percent of its labeled content. It is sterile. Its loss on drying is not more than 1.5 percent. When reconstituted as directed in the labeling, its pH is not less than 5.0 and not more than 7.5. The potassium penicillin G used conforms to the standards prescribed by § 440.80a(a)(1) (i), (v), and (vi) of this chapter.